MENU
+Compare
MREO
Stock ticker: NASDAQ
AS OF
May 13 closing price
Price
$2.32
Change
-$0.18 (-7.20%)
Capitalization
368.88M

MREO Mereo BioPharma Group plc Forecast, Technical & Fundamental Analysis

Mereo BioPharma Group PLC is a United Kingdom (U... Show more

MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for MREO with price predictions
May 13, 2025

Aroon Indicator for MREO shows an upward move is likely

MREO's Aroon Indicator triggered a bullish signal on May 13, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 132 similar instances where the Aroon Indicator showed a similar pattern. In of the 132 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for MREO crossed bullishly above the 50-day moving average on April 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MREO advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MREO as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MREO turned negative on May 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

MREO moved below its 50-day moving average on May 13, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MREO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MREO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MREO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.050) is normal, around the industry mean (14.420). P/E Ratio (0.000) is within average values for comparable stocks, (65.047). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (254.920).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

View a ticker or compare two or three
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

MREO is expected to report earnings to fall 110.00% to 0 cents per share on October 07

Mereo BioPharma Group plc MREO Stock Earnings Reports
Q2'25
Est.
$0.00
Q1'25
Missed
by $0.03
Q4'24
Est.
$-0.01
Q3'24
Est.
$-0.02
Q2'24
Missed
by $0.01
The last earnings report on May 13 showed earnings per share of -1 cents, missing the estimate of 0 cents. With 1.72M shares outstanding, the current market capitalization sits at 368.88M.
A.I. Advisor
published General Information

General Information

a company, which engages in therapeutics that aim to improve outcomes for patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
One Cavendish Place
Phone
+44 3330237300
Employees
33
Web
https://www.mereobiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ECEMX15.02N/A
N/A
Parametric Emerging Markets C
RYENX216.68N/A
N/A
Rydex Energy A
GTEYX46.09N/A
N/A
Gateway Y
BSGRX12.79N/A
N/A
BlackRock Advantage Small Cap Gr R
MSCQX10.86N/A
N/A
Mercer US Small/Mid Cap Equity I

MREO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with CRNX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
-7.20%
CRNX - MREO
45%
Loosely correlated
-7.11%
TRDA - MREO
45%
Loosely correlated
-1.36%
VKTX - MREO
45%
Loosely correlated
-2.00%
IMNM - MREO
41%
Loosely correlated
-0.38%
ATXS - MREO
41%
Loosely correlated
-10.76%
More